Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CG | P48736 | 9/20 | 0.35 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.33 |
| ▸ | BRD4 | O60885 | 1/20 | 0.33 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.33 |
| ▸ | PIK3CD | O00329 | 7/20 | 0.32 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.32 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31489483 | 0.97 | NTRK1 (0.34) | PIK3CGNTRK1BRD4CREBBPPIK3CD | |
| SCHEMBL31489333 | 0.92 | PIK3CG (0.33) | PIK3CGNTRK1PIK3CDRIPK1PIK3CA | |
| SCHEMBL31489825 | 0.89 | PIK3CG (0.31) | PIK3CGNTRK1PIK3CDRIPK1PIK3CA | |
| SCHEMBL31489781 | 0.87 | PIK3CG (0.38) | PIK3CGNTRK1BRD4CREBBPPIK3CD | |
| SCHEMBL31489660 | 0.86 | BRD4 (0.35) | NTRK1BRD4CREBBP | |
| SCHEMBL31489703 | 0.86 | PIK3CG (0.36) | PIK3CGNTRK1CREBBPPIK3CDRIPK1 | |
| SCHEMBL31489539 | 0.84 | PIK3CG (0.34) | PIK3CGPIK3CDRIPK1PIK3CA | |
| SCHEMBL31489386 | 0.84 | PIK3CG (0.35) | PIK3CGNTRK1PIK3CDRIPK1PIK3CA | |
| SCHEMBL31489516 | 0.84 | PIK3CG (0.35) | PIK3CGNTRK1PIK3CDRIPK1PIK3CA | |
| SCHEMBL31489200 | 0.84 | PIK3CG (0.33) | PIK3CGNTRK1PIK3CDRIPK1PIK3CA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025072395-A1 | TRIAZOLOPYRIDINYL COMPOUNDS AS KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2025-04-03 | — | — | WO | disclosed |